1 day-8.41%
1 week-15.51%
Current month-36.29%
1 month-31.75%
3 months-15.73%
6 months-17.71%
Current year-32.19%
1 week 2.36
Extreme 2.3576
4.25
1 month 2.36
Extreme 2.3576
6
Current year 1.87
Extreme 1.87
6.93
1 year 1.87
Extreme 1.87
6.93
3 years 1.87
Extreme 1.87
6.93
5 years 1.87
Extreme 1.87
6.93
10 years 1.87
Extreme 1.87
6.93
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-03
Director of Finance/CFO 38 2025-03-06
Director TitleAgeSince
Director/Board Member 66 2015-04-30
Director/Board Member 71 2024-03-12
Director/Board Member 38 2025-08-10
Date Insider Type Main position Quantity % Market Cap. Importance
10/26/26 Free

Chief Executive Officer

40,000 0.5609%
10/26/26 Free

Chief Financial Officer

250,000 3.5058%
10/26/26 Free

Director

40,000 0.5609%
Change 5-day change 1-year change 3-year change Capi.($)
-8.41%-15.51%+26.91% - 22.38M
+0.25%-9.18%-22.71%+45.41% 212B
-1.47%-17.09%-19.86%-19.77% 149B
+1.18%-11.71%-8.15%-33.16% 131B
-9.46%-10.09%+43.66%+277.64% 98.54B
-5.13%-12.43%+4.15%+52.83% 89.81B
+1.43%-1.30%-24.44%-32.49% 92.84B
+0.44%-3.03%-1.72%-0.27% 67.82B
+0.56%-3.81%-28.54%-23.57% 48.03B
+0.86%-2.44%-18.29%+1.43% 39.3B
Average -1.98%-8.46%-4.90%+29.78% 93B
Weighted average by Cap. -1.27%-9.04%-9.30%+32.72%
Logo GridAI Technologies Corp.
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Employees
-
Date Price Change Volume
26-11-20 US$3.160 -8.41% 125,151
26-11-19 US$3.450 +2.68% 81,387
26-11-18 US$3.360 +1.82% 152,114
26-11-17 US$3.300 0.00% 315,107
26-11-16 US$3.300 -11.76% 430,073
  1. Stock Market
  2. Stocks
  3. GRDX Stock